- Home
- MANH vs CADL Comparison
MANH vs CADL Comparison
Compare MANH & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MANH
- CADL
- Stock Information
- Founded
- MANH 1990
- CADL 1999
- Country
- MANH United States
- CADL United States
- Employees
- MANH N/A
- CADL N/A
- Industry
- MANH Computer Software: Prepackaged Software
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- MANH Technology
- CADL Health Care
- Exchange
- MANH Nasdaq
- CADL Nasdaq
- Market Cap
- MANH 13.0B
- CADL 313.5M
- IPO Year
- MANH 1998
- CADL 2021
- Fundamental
- Price
- MANH $217.86
- CADL $4.94
- Analyst Decision
- MANH Buy
- CADL Strong Buy
- Analyst Count
- MANH 9
- CADL 5
- Target Price
- MANH $221.25
- CADL $19.80
- AVG Volume (30 Days)
- MANH 464.2K
- CADL 697.6K
- Earning Date
- MANH 10-21-2025
- CADL 11-13-2025
- Dividend Yield
- MANH N/A
- CADL N/A
- EPS Growth
- MANH 9.17
- CADL N/A
- EPS
- MANH 3.58
- CADL N/A
- Revenue
- MANH $1,057,690,000.00
- CADL N/A
- Revenue This Year
- MANH $5.15
- CADL N/A
- Revenue Next Year
- MANH $6.66
- CADL N/A
- P/E Ratio
- MANH $60.93
- CADL N/A
- Revenue Growth
- MANH 6.13
- CADL N/A
- 52 Week Low
- MANH $140.81
- CADL $3.79
- 52 Week High
- MANH $312.60
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- MANH 54.37
- CADL 38.14
- Support Level
- MANH $210.19
- CADL $4.60
- Resistance Level
- MANH $220.20
- CADL $5.03
- Average True Range (ATR)
- MANH 5.75
- CADL 0.27
- MACD
- MANH -0.04
- CADL -0.02
- Stochastic Oscillator
- MANH 86.43
- CADL 23.50
About MANH Manhattan Associates Inc.
Manhattan Associates provides software that helps users manage their supply chains, inventory, and omnichannel operations. Customers are generally retailers, wholesalers, manufacturers, and logistics providers. The company was founded in 1990 and serves more than 1,200 customers around the world.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.